tbuckley/cabot-search huggingface dataset:
HLA-G expression and miR-148a, miR-152 in colorectal adenocarcinoma.
Authors: Levent Emirzeoglu, Bulent Karagoz, Ufuk Berber, Alpaslan Tanoglu, Serkan Celik, Alpaslan Ozgun, Oguz Bilgi
Journal: Journal of Clinical Oncology (2015)

e22098 Background: HLA-G is expressed in tumor tissue of several cancer types. Micro-RNA (miR)-148a and miR-152 regulate HLA-G expression in placenta. The different expression of these miR molecules has been reported in malignant tissues. However, the relation between HLA-G and these miRs has not been evaluated in cancer patients. We aimed to investigate HLA-G, miR-148a, and miR152 expressions in colorectal cancer. Methods: Sixty-eight patients with colorectal adenocarcinoma were included to the study. HLA-G and miRs were investigated in tumor tissues and nearest normal colon epithelium. HLA-G was shown with immunohistochemistry. Real time reverse transcriptase chain reaction (RT-PCR) was used for expression of miR-148a and miR-152. miR-148a, and miR152 expressions were compared between malignant and normal tissues and between HLA-G (+) and (–) tumor tissues. Results: HLA-G was immunopositive in tumor tissues from 10 colorectal cancer patients (14.7%). miR-152 expression was lower in tumor than in normal tissue (0.814±0.392 fold vs 1.139±0.438 fold; respectively p < 0.0001), but miR-148a was not different (0.733±0.302 fold 0.778±0.254 vs fold p:0,326). miR-152 is higher in HLA-G positive tumor tissue than in HLA-G negative tumor (0.972±0.16 fold vs 0.787±0.41 fold, respectively p:0,032). However, miR-148a was similar in both HLA-G + and – tumors (0,864±0,18 fold vs 0,710±0,31 fold, respectively p:0,121). miR expressions were not related to tumor grad, lymph node or distance metastasis status. Conclusions: miR-152 is lower in tumor tissue with colorectal adenocarcinoma than non-malignant colonic epitelium. Expression of miR-152 is higher in HLA-G (+) tumors than (-) tumors.
Aneuploidy of anaplastic lymphoma kinase (ALK) gene and association with non squamous lung cancer patient characteristics and outcomes.
Authors: Taofeek Kunle Owonikoko, Marquita Nelson, Seog Yun Park, Sungjin Kim, Conor Ernst Steuer, Madhusmita Behera, Zhengjia Chen, Erica Han, Mukesh Kumar, Vinicius Ernani, Nabil F. Saba, Fadlo Raja Khuri, Suresh S. Ramalingam, Michael R. Rossi
Journal: Journal of Clinical Oncology (2015)

7549 Background: ALK gene translocation resulting in aberrant activation of ALK signaling is a genetic driver in subsets of NSCLC. Aneuploidy of the ALK gene is also frequently observed but its impact has not been well studied. Methods: We analyzed the results of molecular tests performed in a CLIA-certified lab for lung cancer patients treated at our institution. Patient demographics, treatment and outcome data were retrieved from the electronic records. Univariate and multivariable analysis was performed to test for association between ALK gene aneuploidy, percentage of aneuploid cells, minimum and maximum number of ALK gene copies per cell and the following covariates: ALK gene rearrangement, gender, stage, race, age, PFS and OS. Survival was estimated by the Kaplan-Meier method and compared between defined groups using a Cox proportional hazards model and log rank test. Results: We analyzed data from 259 patients, male (48%); Black (33%), Asian (4%), White (63%); median age 65yrs; stage: I (32%), II (12%), III (16%) and IV (40%). The median PFS and OS were 14.4 months (95% CI: 9.7 – 20.1) and 79.7 months (95% CI: 22.9 – NA), respectively. ALK FISH rearrangement was present in 3 (4.8%) of 63 patients tested by FISH. Aneuploidy of the ALK gene was present in 46 (73%) cases with 40% aneuploid cells per case. Minimum and maximum number of copies of ALK gene in aneuploid cells were 2.63 (± 0.61) and 4.02 (± 2.03), respectively. There was no association between ALK gene aneuploidy and patient characteristics but ALK gene aneuploidy, percentage aneuploid cells and high ALK polysomy were negatively correlated with presence of ALK FISH rearrangement. Absence of aneuploidy (HR: 0.29; 0.09-0.95; p,0.040) and higher stage at diagnosis were independently associated with a higher risk of progression on multivariable analysis. Conclusions: There is inverse association of ALK gene aneuploidy and ALK gene rearrangement. The association between ALK polysomy and higher risk of disease progression is worthy of further study to elucidate the underlying biology.
Identification of HPV molecular triggers in cutaneous squamous cell carcinoma.
Authors: Gang Shi, Mohammed Lilo, Max Fischer, Denver Lough, Anne C Fischer, Anthony P. Tufaro
Journal: Journal of Clinical Oncology (2015)

e20084 Background: Cutaneous squamous cell carcinoma (SCC) a malignant tumor derived from epidermal keratinocytes and occurs predominately in sun-exposed skin. Organ transplant recipients have 60-250 times more likely to develop SCC than the immunocompetent population and the risk of SCC development increases with time posttransplant. Cutaneous SCC is the second most common skin cancer, affecting 700,000 people each year and up to 8,800 people died from the disease in 2012. Human papillomavirus (HPV) is a DNA virus from the papillomavirus family, with more than 100 HPV genotypes characterized. Although the significance of specific types of HPV is well recognized in cervical and anogenital SCC, as well as a subset of oropharyngeal SCC, its contributing role in cutaneous SCC oncogenesis is still being debated. A retrospective study was undertaken to study the oncogenesis of HPV presence and its types in aggressive cutaneous SCC. Methods: Formalin-fixed paraffin embedded (FFPE) archival patient tissue blocks with a clear aggressive cutaneous SCC history were deparaffinized and underwent DNA isolation and regular HPV-PCR with HPV specific primers: GP5+, 5’-TTTGTTACTGTGGTAGATACTAC-3’ and GP6+, 5’-GAAAAATAAACTGTAAATCATATTC-3’ to identify HPV presence. HPV positive PCR products were cloned into T4-Vectors and underwent DNA sequencing to identify HPV genotypes in cutaneous SCC. Results: Total 36 aggressive cutaneous SCC blocks were tested by HPV-PCR, among which 15 blocks were HPV-16, 1 block was HPV-10 and 15 blocks were HPV test negative. HPV positive blocks account for 51.6%, among which HPV-16 accounts for 48.4% and HPV-10 accounts for 3.2%. HPV negative blocks account for 48.4%. Conclusions: (i) HPV infection is very popular in aggressive cutaneous SCC patients and HPV-16 is the most prevalent HPV type, accounting for 93.8% HPV infections. HPV infection may not only be a risk factor but also a contributing factor to aggressive cutaneous SCC oncogenesis; (ii) HPV-10 was first identified in an aggressive cutaneous SCC patient, which may co-relate to the oncogenesis of aggressive cutaneous SCC.
Effect of very early angiotensin-converting enzyme inhibition on left ventricular dilation after myocardial infarction in patients receiving thrombolysis
Authors: Pieter J de Kam, Adriaan A Voors, Maarten P van den Berg, Dirk J van Veldhuisen, Jan Brouwer, Harry J.G.M Crijns, Claudio Borghi, Ettore Ambrosioni, Judith S Hochman, Thierry H LeJemtel, Jan-Herre Kingma, Martin St. John Sutton, Wiek H van Gilst
Journal: Journal of the American College of Cardiology (2000)
SAT0093 Success-1 in osteoarthritis: celecoxib demonstrates similar efficacy to the conventional nsaids, diclofenac and naproxen, in patients with osteoarthritis treated in 39 countries in 6 continents
Authors: G Singh, J Goldstein, J Fort, A Bello, S Boots
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> The SUCCESS-1 trial is the largest controlled study comparing celecoxib and NSAIDs. This long-term trial was intended to closely parallel clinical practice in a variety of worldwide settings to assess the overall efficacy, tolerability, and safety of celecoxib and NSAIDs with a large group of diverse physicians. <h3>Objectives</h3> This study compared the efficacy, safety, and tolerability of celecoxib 200 and 400 mg per day and the most commonly prescribed NSAIDs in 39 countries in the treatment of the signs and symptoms of osteoarthritis (OA) of the knee, hip, and hand. <h3>Methods</h3> The SUCCESS-1 in OA trial is a large double-blind, randomised study conducted in patients from 1,142 centres in Europe and South Africa, Asia, Latin America, and the US and Canada. Patients were treated for 12 weeks using celecoxib (200 or 400 mg/d) and the most common regimens of NSAIDs (naproxen 1000 mg/d in US and Canada and diclofenac 100 mg/d in all other countries). Assessments of arthritis efficacy were performed by country or region. Safety and tolerability were assessed globally. <h3>Results</h3> Of the 13,194 intent-to-treat patients, the mean age was 62 years, and the majority were female (76%) and caucasian (80%). Patients in each group had comparable baseline aspirin use and history of upper GI bleeding. Arthritis assessments were based on mean changes in baseline arthritis pain by VAS and night pain at week 12. Data is presented from European countries/regions. No significant differences between celecoxib 200 mg/day and celecoxib 400 mg/day compared to diclofenac 100 mg/day were observed. In addition, celecoxib 200 mg/day and 400 mg/day were similar in efficacy. Comparable efficacy between celecoxib and NSAIDs was also demonstrated in other countries/regions that participated in the study. <h3>Conclusion</h3> This study adds substantially to the available efficacy data on celecoxib. It expands the data globally on the efficacy of celecoxib to various settings that closely follow local clinical practice. Celecoxib demonstrated similar efficacy to the most commonly prescribed regimen of diclofenac in the treatment of OA. Sponsored by Pharmacia Corporation and Pfizer Inc.
Left Atrial Mechanical Function and Incident Ischemic Cerebrovascular Events Independent of AF
Authors: Mohammadali Habibi, Mytra Zareian, Bharath Ambale Venkatesh, Sanaz Samiei, Masamichi Imai, Colin Wu, Lenore J Launer, Steven Shea, Rebecca F Gottesman, Susan R Heckbert, David A Bluemke, João A C Lima
Journal: JACC. Cardiovascular imaging (2019)
Pseudo–Ventricular Tachycardia, Pseudo–Atrial Fibrillation, and Pseudo–Atrial Flutter in a Patient With Parkinson Disease
Authors: Wesseem Osman, Matthew Hanson, Adrian Baranchuk
Journal: JAMA Internal Medicine (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Tumor molecular profiling (MP) platform: Utility in phase I trials patients selection.
Authors: Christian Diego Rolfo, Eduardo Castanon Alvarez, Massimiliano Grassi, Marc Peeters, Patrick Pauwels
Journal: Journal of Clinical Oncology (2015)

e22155 Background: Clinical phase I trials are no longer aimed to study only pharmokinetics/pharmacodynamics or toxicity, but also investigating possible tumor responses, especially if patients (pts) are properly selected. Introduction of new biomarkers from phase I clinical trials, has contributed to an unexpected success which has made regulatory agencies approve drugs based on early results. MP may be helpful in order to enroll patients in clinical trials based on a molecular rational. Methods: We performed 38 MP in pts with no standard treatment available. A commercial platform for MP (CARIS), which includes next generation sequencing (NGS), quantitative PCR (qPCR), chromogenic in situ hybridization (CISH) and immunohistochemistry (IHC) techniques was used. Results: From a total of 36 pts, tumor distribution was 10 lung (26.3%), 6 colorectal (15.8%), 4 breast (10.5%), 2 ovarian (5.3%), 2 pancreatic (5.3%), 2 salivary glands (5.3%), 1 squamous cell esophagus (2.6%), 1 gastric (2.6%), 1 leyomiosarcoma (2.6%), 1 cervix (2.6%), 1 hepatocellular (2.6%), 1 clear cell renal (2.6%), 1 gallbladder (2.6%), 1 thymoma (2.6%) and 3 unknown origin tumors (7.9%). p53 was the most frequently mutated gene (39.5%) followed by KRAS (18.4%; exon 2: 85.7%, codon 12: 71.4%). TOPO1 was overexpressed in 24 pts (63.2%), followed by TOP2A (55.3%), MGMT (55.3%) and PTEN (52.6%). cMET was overexpressed in 10 pts (26.3%) and PD1 in 9 pts (23.7%), whereas PDL1 in 6 pts (15.8%). Ten out of 36 pts (27.8%) enrolled in phase I trials. Nine (90%) were included according to the results of the MP. Two pts (lung and salivary gland cancer) presented BRAF mutations and were given RAF inhibitors by compassionate use. Conclusions: Identification of druggable targets in clinical trials may improve the outcome in terms of response, when a rational selection is performed, even in non-selective targeted trials (pk/pd designs). Also, MP may detect some unexpected mutations, which may lead to use non-standard therapeutic options. Even when no mutations are detected, IHC may be a feasible approach to choose an accurate treatment. There is debate about the timing to perform MP, but from our experience, it should not be left as a last resource, since pts may benefit from it in earlier line setting.
SAT-348-Low frequencies of lifestyle interventions and liver-specific medications in a multicentric prospective real world NAFLD cohort: The fatty liver assessment in Germany (FLAG) study
Authors: Wolf Peter Hofmann, PD Dr. Schattenberg Jörn, Nektarios Dikopoulos, Frank Lammert, Renate Heyne, Jeannette Schwenzer, Michael P. Manns, Marion Muche, Lisa Schubert, Patrick Ingiliz, Anna Schmidt, Kerstin Stein, Stefan Zeuzem, Peter Buggisch
Journal: Journal of Hepatology (2019)
THU-372-Exosomes from human umbilical cord mesenchymal stem cells promote liver regeneration in aged mice after major hepatectomy via activating sirtuin1 pathway
Authors: Liang Chen, Jun Zheng, Qing Yang, Jianye Cai, Jiebin Zhang, Tongyu Lu, Jia Yao, Yingcai Zhang, Yang Yang
Journal: Journal of Hepatology (2019)
TCTAP A-019 Paradoxical Elevation of Cholesterol Efflux Capacity During Acute Coronary Syndrome in Young Heterogenous Asians
Authors: Nicholas Yul Chye Chua, Raja Ezman Raja Shariff, Johan Rizwal Ismail, Chiao Wen Lim, Mohd Kamal Mohd Arshad, Rizmy Najme Khir, Khairul Shafiq Ibrahim, Hafisyatul Aiza Zainal Abidin, Zubin Ibrahim, Effarezan Abdul Rahman, Sazzli Kasim
Journal: Journal of the American College of Cardiology (2019)
Characterization of QuantiFERON-TB-Plus results in latent tuberculosis infected patients with or without immune-mediated inflammatory diseases
Authors: Teresa Chiacchio, Elisa Petruccioli, Valentina Vanini, Gilda Cuzzi, Umberto Massafra, Gianpiero Baldi, Assunta Navarra, Rossana Scrivo, Claudio Mastroianni, Ilaria Sauzullo, Carmela Esposito, Fabrizio Palmieri, Fabrizio Cantini, Delia Goletti
Journal: Journal of Infection (2019)
SAT-481-Intratumoral mast cell infiltration and recurrence of hepatocellular carcinoma in patients undergoing orthotopic liver transplantation
Authors: Nataliya Rohr-Udilova, Kaoru Tsuchiya, Martina Salzmann, Gerald Timelthaler, Erika Jensen-Jarolim, Rolf Schulte-Hermann, Robert Eferl, Merima Herac, Judith Stift, Georg Oberhuber, Wolfgang Sieghart, Thomas Reiberger, Markus Peck-Radosavljevic, Matthias Pinter, Michael Trauner
Journal: Journal of Hepatology (2019)
Abstract 20070: Pulmonary Pressure Improves but Remains Pathologically Elevated During Exercise After Pulmonary Endarterectomy
Authors: Farhad Waziri, Søren Mellemkjær, Tor S Clemmensen, Lars B Ilkjær, Sten L Nielsen, Steen H Poulsen
Journal: Circulation (2017)

Background: Pulmonary endarterectomy (PEA) is a potentially curative treatment of chronic thromboembolic pulmonary hypertension (CTEPH), resulting in improved functional status, hemodynamics and ov...
A Phase I Trial of 90Y-BC8-DOTA (Anti-CD45) Monoclonal Antibody in Combination with Fludarabine and TBI As Conditioning for Allogeneic Peripheral Blood Stem Cell Transplant to Treat High Risk Multiple Myeloma
Authors: Sherilyn A Tuazon, Brenda M. Sandmaier, Johnnie J. Orozco, Ajay K. Gopal, Leona A. Holmberg, Pamela S. Becker, Sally J. Lundberg, Brian G. Till, Margaret E. Nartea, Ted Gooley, Darrell R. Fisher, Joseph G. Rajendran, Oliver W. Press, William I. Bensinger, Damian J. Green
Journal: Blood (2017)
Missed opportunities for HIV testing in people diagnosed with HIV, Estonia, 2014 to 2015
Authors: Kristi Rüütel, Liis Lemsalu, Sirly Lätt, Jevgenia Epštein
Journal: Eurosurveillance (2019)

Studies of missed opportunities for earlier diagnosis of HIV have shown that patients with undiagnosed HIV often present to healthcare settings numerous times before eventually receiving their diagnosis.The aim of the study was to assess missed opportunities for HIV testing among people newly diagnosed with HIV.In this observational retrospective study, we collected data from the Estonian Health Board on new HIV cases in people aged 16–49 years diagnosed in 2014–15 and from the Estonian Health Insurance Fund database for treatment invoices on their contacts with healthcare services in the 2 years preceding diagnosis. Diagnoses on treatment invoices were categorised as HIV indicator conditions using ICD-10 codes.Of 538 newly diagnosed HIV cases (62.5%; 336 men), 82% had visited healthcare services at least once during the 2 years before HIV diagnosis; the mean number of visits was 9.1. Of these, 16% had been tested for HIV and 31% had at least one ICD-10 code for an HIV indicator condition on at least one of their treatment invoices. In 390 cases of HIV indicator conditions, only 5% were tested for HIV. Of all new HIV cases aged 20–49 years from high-incidence regions (defined as priority groups in national testing guidance), 18% had been tested.The HIV testing rate in the 2 years before an HIV diagnosis was very low, even in the presence of an HIV indicator condition. This emphasises the importance of implementing the Estonian HIV testing guidelines.
Plasmacytoid Dendritic Cells and Infected Cells Form an Interferogenic Synapse Required for Antiviral Responses
Authors: Sonia Assil, Séverin Coléon, Congcong Dong, Elodie Décembre, Lee Sherry, Omran Allatif, Brian Webster, Marlène Dreux
Journal: Cell Host & Microbe (2019)
Abstract 14994: Sedation and Anesthesia Related Adverse Events in Pediatric and Congenital Cardiac Catheterization
Authors: C. Huie Lin, Sanyukta Desai, Ramzi Nicolas, Kimberlee Gauvreau, Susan Foerster, Anshuman Sharma, David Balzer, Lisa Bergersen
Journal: Circulation (2012)

Background: Sedation or anesthesia is critical to preparing the pediatric patient for cardiac catheterization, and procedural sedation with spontaneous respiration is often sufficient, however the ...
Mutation yield of a 34-gene next-generation sequencing test in community-based tumor samples.
Authors: Kevin Z. Qu, Heather Sanders, Joseph Catanese, Andrew Grupe, Hai-Rong Li, David Ross, James Prentice, Lin Ma, Beryl Crossley, Cindy Barlan, Xi Zhang, Jay Wohlgemuth, Anthony Sferruzza, John J. Sninsky, Feras Hantash, Frederic Waldman
Journal: Journal of Clinical Oncology (2015)

e22132 Background: Several targeted therapies have been approved for treatment of solid tumors. Identification of gene mutations associated with response to these targeted therapies is rapidly progressing. We developed and validated a 34-gene next-generation sequencing (NGS) panel and used this to test community-based samples sent for routine molecular testing for actionable gene mutations. Methods: A laboratory-developed NGS test on an Ion Torrent PGM sequencer was used to determine mutation profiles for 121 consecutive, de-identified FFPE tissue samples collected from patients diagnosed with melanoma (n = 31), lung (n = 27), colorectal (n = 33), and breast cancer (n = 30). NGS results were compared to those of the routine single-gene molecular tests. Results: Twenty-four (20%) samples had mutations detected by the originally requested tests, all of which were also detected by NGS. However, NGS detected at least 1 additional mutation not detected by the original test in 92 (76%) of the 121 samples. Of the additional mutations detected, 16 were actionable according to NCCN guidelines (3 BRAF [2 V600E and K483Q] in melanoma specimens; 2 KRAS [A146T and L19F], 2 BRAF [2 V600E] and 1 NRAS [Q61K] in colorectal cancer; and 2 EGFR [E746-A750 and R680Q] and 6 KRAS [A146T, G12C, G12V, Q22K, G12A and G13C] in lung cancer). Most of the additional mutations detected by NGS were in regions not covered by the routine molecular test(s); in the other cases, NGS may have provided greater sensitivity than the routine test. Overall, mutations were detected in 21 of the 34 genes included in the NGS panel, 17 of which were detected in multiple tumor types. The most frequently mutated gene was TP53 (64/121), but 83% (100/121) of the specimens harbored mutations in at least 1 gene other than TP53. Conclusions: This NGS assay frequently detected actionable mutations not identified by routine single-gene tests. These findings suggest that broader mutation profiling of solid tumors, as with the 34-gene NGS mutation panel, could provide additional information for treatment selection in a substantial proportion of cases.
Exclusive: Partnering with alcohol industry on public health is not okay, WHO says
Authors: Ingrid Torjesen
Journal: BMJ (2019)

The World Health Organization will not engage with the alcohol industry when developing alcohol policy or implementing public health measures, its staff have been told, and any government seeking advice from a collaboration with industry should be warned of the dangers.

The message that partnering, collaborating, taking funding, and even talking with the alcohol industry on some subjects is not acceptable has been laid out in an internal note to WHO staff.

“The public health objectives of WHO in relation to alcohol should serve as the basis for any interaction with the alcohol industry,” says the email, seen by The BMJ .

“The nature of interaction between the WHO secretariat and the alcohol industry should be limited to a …
THU-128-Renal safety in 3,264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life study
Authors: Roberta D’ambrosio, Luisa Pasulo, Alessia Giorgini, Angiola Spinetti, Caterina Uberti-Foppa, Ilaria Fanetti, Massimo Puoti, Alessio Aghemo, Paolo Viganò, Maria Vinci, Barbara Menzaghi, Andrea Lombardi, Angelo Pan, Marie Graciella Pigozzi, Paolo Antonio Grossi, Sergio Lazzaroni, Ombretta Spinelli, Pietro Invernizzi, Franco Maggiolo, Agostino Colli, Chiara Molteni, Natalia Terreni, Antonella d’Arminio Monforte, Paolo Del Poggio, Maria Teresa Taddei, Silvia Colombo, Alessandra Brocchieri, Sherrie Bhoori, Elisabetta Buscarini, Riccardo Centenaro, Monia Mendeni, Alberto Colombo, Mariella Di Marco, Elena Dionigi, Daniele Bella, Marta Borghi, Massimo Giovanni Zuin, Serena Zaltron, Franco Noventa, Pietro Lampertico, Stefano Fagiuoli
Journal: Journal of Hepatology (2019)
TCTAP A-121 Fully Percutaneous Femoro-popliteal Bypass for Treatment of Long-complex Lesions: 1-year Results from the DETOUR I Trial
Authors: Dainis Krievins, Gregorz Halena, Roberts Rumba, Natalija Ezite, Edgars Zellans, Kaspars Kisis, Marcis Gedins, Janis Savlovskis
Journal: Journal of the American College of Cardiology (2019)